Ignite Creation Date:
2024-05-06 @ 10:21 AM
Last Modification Date:
2024-10-26 @ 12:28 PM
Study NCT ID:
NCT03230318
Status:
COMPLETED
Last Update Posted:
2023-12-19
First Post:
2017-07-24
Brief Title:
Derazantinib in Subjects With FGFR2 Gene Fusion- Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma
Sponsor:
Basilea Pharmaceutica
Organization:
Basilea Pharmaceutica
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Combined Hepatocellular and Cholangiocarcinoma |
| Intrahepatic Cholangiocarcinoma |
Keywords:
| Name | View |
|---|---|
| derazantinib | View |
| iCCA | View |
| intrahepatic cholangiocarcinoma | View |
| FGFR2 gene fusion or FGFR2 gene mutation or amplification | View |
| biliary cancer | View |
| bile duct cancer | View |
| FGFR2 gene rearrangement | View |
| liver cancer | View |
| targeted therapy | View |
| combined hepatocellular and cholangiocarcinoma | View |
| cHCC-CCA | View |